TITLE

Phase-3 sunitinib trial in metastatic colorectal cancer stopped

PUB. DATE
August 2009
SOURCE
Hem/Onc Today;8/10/2009, Vol. 10 Issue 15, p33
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article reports on the decision of Pfizer to discontinue its phase-three clinical drug trial on sunitinib for treating metastatic colorectal cancer.
ACCESSION #
43476060

 

Related Articles

  • Days of IOP control help determine drug effectiveness. Zimmerman, Thom J. // Ophthalmology Times;1/15/2007, Vol. 32 Issue 2, p43 

    The article evaluates the drug latanoprost (Xalatan), prescribed for patients undergoing treatment for primary open-angle glaucoma, which is manufactured by Pfizer Inc.

  • ELELYSO.  // Monthly Prescribing Reference;Jul2012, Vol. 28 Issue 7, pA4 

    The article offers brief information on Elelyso drug from Pfizer Inc.

  • MAKE A HABIT OF BREATHING BETTER. Arnold, Matthew // Medical Marketing & Media;Jan2007, Vol. 42 Issue 1, p10 

    The article evaluates Spiriva, medication for chronic obstructive pulmonary disease from Pfizer Inc.

  • Duavee.  // MPR - Pharmacist's Edition;Summer2014, Vol. 8 Issue 2, pA8 

    The article offers brief information on the drug Duavee from Pfizer Inc.

  • Do Your Really Need Maximum-Dose Lipitor? Cohen, Jay S. // Life Extension;Aug2007, Vol. 13 Issue 8, p48 

    The article evaluates the Lipitor cholesterol-lowering drug from Pfizer Inc.

  • Pharma: Clinic Roundup.  // BioWorld Today;6/10/2013, Vol. 24 Issue 110, p8 

    The article announces the start of Pfizer Inc.'s Phase I trial of PF-06140293, a similar version of Humira, to measure pharmacokinetic values of the drug.

  • Pharma: Clinic Roundup.  // BioWorld Today;11/19/2012, Vol. 23 Issue 225, p7 

    This article reports on the failure of Pfizer Inc.'s 165-milligram (mg) dose and 330-mg dose of pregabalin controlled-release (CR) formulation in a Phase III study testing its use as a once-daily therapy for partial onset seizure.

  • Called Off.  // Pharmaceutical Executive;Oct2000, Vol. 20 Issue 10, p160 

    Reports that the Phase III trials of prinomastat, a matrix matalloprotease inhibitor, was discontinued by Pfizer. Reasons for the discontinuation of the trials; Details on other trials of prinomastat that are underway.

  • Pfizer accused of testing new drug without ethical approval. Wise, Jacqui // BMJ: British Medical Journal (International Edition);01/27/2001, Vol. 322 Issue 7280, p194 

    Addresses allegations that the drug manufacturer Pfizer did not obtain official approval before testing a new drug on children during a meningitis epidemic in Nigeria in 1996. How Pfizer supposedly did not properly receive ethical approval; Presence of a Pfizer team in Kano, Nigeria during an...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics